ClinicalTrials.gg
Not yet recruitingNCT05946967TENSUpdated Jul 14, 2023

Colon Transit Study for Chronic Constipation Assessment and Therapy by Biofeedback With and Without TENS

An interventional study of Biofeedback with TENS and Biofeedback only in Constipation, sponsored by Sanjay Gandhi Postgraduate Institute of Medical Sciences. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-14.

Sponsored by Sanjay Gandhi Postgraduate Institute of Medical Sciences · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 1 month ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

One of the most challenging functional gastrointestinal illnesses (FGID) to manage is constipation, which is a widespread issue. The fact that constipation can be caused by a variety of conditions, including slow colon transit, faecal evacuation disorder, or a combination of both slow colon transit and faecal evacuation disorder, is one of the main reasons it is challenging to treat. Treatment options vary based on the pathogenetic mechanism; for instance, biofeedback, botulinum toxin injections in the puborectal sling, or transcutaneous electrical nerve stimulation (TENS) are required to treat faecal evacuation problem. On the other hand, prucalopride and other colokinetic drugs as well as drugs that promote high amplitude propagating contractions, including bisacodyl and sodium pyrosulphate, are used to treat slow transit constipation. Sometimes faecal evacuation disorders that inhibit the evacuation of the transit markers can cause slow colon transit times; these secondary sluggish colon transit times have been shown to improve with biofeedback therapy alone. Even though the causes of faecal evacuation disorders are not fully understood, it is known that abnormal neuromuscular function is the result. A few workers have stimulated the posterior tibial nerve, another sacral plexus branch, non-invasively with TENS. Studies on the use of biofeedback in the treatment of patients with faecal evacuation problems are lacking. Accordingly, we wish to undertake a prospective study with following aims: (i) To assess safety and efficacy of colon transit study by an indigenous radio opaque marker to identify the mechanism of constipation and to assess outcome of treatment (improvement of transit time). (ii) To assess the efficacy of pathogenesisdirected therapy such as biofeedback with or without TENS for posterior tibial nerve to treat fecal evacuation disorder. (iii) To assess colon transit following treatment of fecal evacuation disorder with either biofeedback alone or biofeedback with TENS for posterior tibial nerve.

Read the detailed description

Introduction Constipation is a common problem and one of the most difficult functional gastrointestinal diseases (FGID) to treat. An Asian survey showed that among patients with FGID, constipation patients are most dissatisfied with treatment . One of the major reasons why constipation is difficult to treat is because of the fact that constipation may result from multiple factors like slow colon transit, fecal evacuation disorder, or a combination of both slow colon transit and fecal evacuation disorder . Until and unless the exact cause is identified, the empirical treatment with laxatives does not work. Treatment varies depending upon the pathogenetic mechanism, for example, fecal evacuation disorder needs to be treated with biofeedback , botulinum toxin injection in the puborectal sling, or transcutaneous electrical nerve stimulation (TENS) . On the other hand, slow transit constipation is treated with colokinetic agents such as prucalopride and agents stimulating high amplitude propagated contractions such as bisacodyl and sodium pyrosulphate. Sometimes colon transit time may be slow secondary to fecal evacuation disorder mitigating evacuation of the transit markers; such secondary slow colon transit has been shown to improve with biofeedback therapy alone.

Fecal evacuation disorders are diagnosed with anorectal manometry, balloon expulsion test, and barium or magnetic resonance imaging defecography. On the other hand, slow transit constipation is diagnosed by radio-nuclide colon transit study, a colon transit study using radio-opaque markers and smart pills, etc. Since these investigations are not widely available, it becomes difficult to detect the mechanism of constipation in practice by many physicians and gastroenterologists. Two tests that can be easily performed in office practice by most physicians and gastroenterologists include: (i) balloon expulsion test, (ii) colon transit time (CTT) by opaque markers. Detecting these pathophysiological mechanisms of chronic constipation is expected to provide personalized therapy for these patients.

Though mechanisms of fecal evacuation disorders are poorly understood, yet it is known that it results from abnormal neuromuscular function resulting in lack of increase in intra-rectal pressure during attempted defecation and failure of relaxation of pelvic floor muscles. This led to some workers to treat these patients with sacral nerve stimulation, which is primarily used to treat fecal incontinence. However, sacral nerve stimulation is quite invasive, requires major surgical procedure and is associated with multiple complications, including infection. A few workers have used non-invasive TENS to stimulate posterior tibial nerve, which is also a branch of sacral plexus. However, there is lack of studies to treat patients with fecal evacuation disorders with or without biofeedback, which is considered, the first-line therapy for fecal evacuation disorder. Accordingly, we hypothesized that, (i) the office-based investigation such as colon transit study using radio-opaque markers will be useful to diagnose fecal evacuation disorder, which will be able to direct further therapy, (ii) biofeedback with TENS for posterior tibial nerve will be superior to biofeedback alone to treat fecal evacuation disorder, and (iii) successful treatment of fecal evacuation disorder with either biofeedback alone or biofeedback with TENS for posterior tibial nerve will improve colon transit as assessed by radio-opaque marker study.

Accordingly, we wish to undertake a prospective study with following aims:

(i) To assess safety and efficacy of colon transit study by an indigenous radio opaque marker to identify the mechanism of constipation and to assess outcome of treatment (improvement of transit time).

(ii) To assess the efficacy of pathogenesis-directed therapy such as biofeedback with or without TENS for posterior tibial nerve to treat fecal evacuation disorder.

(iii) To assess colon transit following treatment of fecal evacuation disorder with either biofeedback alone or biofeedback with TENS for posterior tibial nerve.

Methodology

Inclusion criteria:

i) Patient with refractory chronic constipation ii) >18 years of age Exclusion criteria i) Patient with uncontrolled diabetes/ untreated thyroid/ organic disease ii) No lower limb iii) \<18 years of age

Fifty patients with chronic constipation will undergo the below-mentioned tests as per standardized protocol. It is important to mention here that all these tests are standard of care for these patients. The tests are: (i) anorectal manometry, (ii) balloon expulsion, (iii) colon transit study by an indigenous radio-opaque marker according to the standard of care, and (iv) defecography (either barium or magnetic resonance imaging).

The diagnostic criteria for fecal evacuation disorder will be as follows: positive result in 2 of the following tests - a) anorectal manometry with defecation index of \<1.4, b) abnormal balloon expulsion test, c) abnormal defecography.

The ability of CTT to diagnose fecal evacuation disorder and slow transit constipation among these subjects will be assessed. Patients with fecal evacuation disorders diagnosed as above will be subjected to daily biofeedback with one group receiving TENS daily and the other group receiving sham stimulations. These treatments will be given for 10 days. The treatment group shall be decided based upon the understanding with patients and mutual decision of the doctor and the patient. Standard treatment of stimulative laxatives will be given to patients with bloating and ispaghula husk to patients without bloating.

No patient will have to pay for biofeedback and TENS. The other tests (anorectal manometry, balloon expulsion, colon transit study, and defecography) are standard of care for patients with constipation. Follow up will be done at 1 month and 3 months as described in figure 2.

Outcome measures i) Constipation severity questionnaire will be used to assess the Constipation Scoring System.

ii) Number of spontaneous bowel movements, time spent in the toilet, stool form (according to Bristol stool chart) will be assessed with a stool diary.

iii) Dose of laxatives used. iv) After the end of treatment, colon transit study will be repeated to assess its improvement.

02

Conditions studied

  • Constipation

Browse trials for

Keywords

  • CTT
  • IBS-C
  • Functional-constipation
03

In context

Constipation

1,046 studies on the registry are indexed under Constipation; 161 are open to participants now.

This study's planned enrollment of 50 is below the median of 75 across 884 interventional studies indexed under Constipation.

Browse Constipation studies →

Lead sponsor

Sanjay Gandhi Postgraduate Institute of Medical Sciences is the lead sponsor of 38 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • i) Patient with chronic constipation ii) 18-65 years of age

Exclusion criteria

Exclusion Criteria:

  • i) Patient with uncontrolled diabetes/ untreated thyroid/ organic disease ii) No lower limb iii) \<18 years of age iv) >65 years of age
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Biofeedback with TENS

    Patients with constipation will undergo biofeedback treatment along with transcutaneous electrical stimulation (TENS)

    Other: Biofeedback with TENS

  • Sham comparator
    Biofeedback only

    Patients with constipation will undergo biofeedback treatment only

    Other: Biofeedback only

Interventions

  • OtherBiofeedback with TENS

    Constipation patients will be given biofeedback treatment along with transcutaneous electrical stimulation (TENS) of posterior tibial nerve

  • OtherBiofeedback only

    Constipation patients will be given biofeedback treatment only

06

What researchers measure

Primary outcomes

  1. Constipation severity

    Constipation severity questionnaire will be used to assess the Constipation Scoring System

    Time frame: 3 months

  2. Bowel movement assessment

    Number of spontaneous bowel movements, time spent in the toilet, stool form (according to Bristol stool chart) will be assessed with a stool diary

    Time frame: 3 months

  3. Treatment effect

    After the end of treatment, colon transit study will be repeated to assess its improvement.

    Time frame: 3 months

Secondary outcomes

  1. Dose of laxatives

    Dose of laxatives used will be recorded

    Time frame: 3 month

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Sep 2023, 2 months later.

Of 243 non-industry interventional studies with no phase under Constipation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 2 months is below that.

Counting every sponsor, half of 314 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Jul 14, 2023
StartEst.
Jul 20, 2023
Primary completionEst.
Sep 30, 2023
CompletionEst.
Dec 31, 2023
Last update
Jul 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05946967
Lead sponsor
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Jul 20, 2023 (estimated)
Primary completion
Sep 30, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Jul 14, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion